Perspective Therapeutics, Inc.
CATXNYSEHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $1.4M | $0 | $10.1M | $9.7M |
| Operating income | −$113.6M | −$90.9M | −$40.9M | −$6.4M | −$3.4M | −$3.5M |
| Net income | −$103.1M | −$79.3M | −$46.5M | −$7.3M | −$745,000 | −$3.4M |
| Total assets | $267.0M | $341.1M | $97.9M | $58.1M | $70.4M | $8.7M |
| Total liabilities | $59.9M | $50.4M | $22.7M | $3.4M | $3.0M | $3.0M |
| Equity | $207.0M | $290.7M | $75.2M | $61.3M | $67.4M | $5.7M |
| EPS (diluted) | $-1.40 | $-1.23 | $-1.74 | $-0.05 | $-0.01 | $-0.05 |
| Shares out. | 74.1M | 586.9M | 281.8M | 142.1M | 141.9M | 68.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −49.8%
- Return on assets
- −38.6%
- Return on capital (ROCE)
- −47.7%
- Liabilities / assets
- 22.5%
- Debt / equity
- 0.29×
- Book value / share
- $2.80
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -0.38distress
- Accruals / assets
- −7.7%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2006
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Recruitingreadout ~2027-12-31MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- Phase 1/2Recruitingreadout ~2028-01-31Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Phase 1/2Recruitingreadout ~2029-11-26Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Morgan StanleyPassive (13G)May 12, 2026
- Blackrock, Inc.Passive (13G)Apr 27, 2026
- Avidity Partners Management LpPassive (13G)Mar 10, 2026
- Commodore Capital LpPassive (13G)Feb 9, 2026
- Tcg Crossover Gp Ii, LlcPassive (13G)Feb 6, 2026
- Qatar Investment AuthorityPassive (13G)Feb 5, 2026
- Fmr LlcPassive (13G)Dec 5, 2025
- Janus Henderson Group PlcPassive (13G)Feb 14, 2025
- Schultz Michael KPassive (13G)Feb 5, 2024
- Johnson FrancesPassive (13G)Feb 5, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 12.6M | 8.0 | -2.9% |
| Apr 30, 2026 | 13.0M | 8.4 | -4.9% |
| Apr 15, 2026 | 13.7M | 18.0 | -3.2% |
| Mar 31, 2026 | 14.1M | 7.3 | +39.9% |
| Mar 13, 2026 | 10.1M | 7.8 | +4.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventJun 1, 2026
- Shareholder voteMay 27, 2026
- Other material eventMay 22, 2026
- Results of operations · Other material eventMay 11, 2026
- Results of operations · Other material eventMay 4, 2026
- Other material eventApr 20, 2026
- Other material eventApr 1, 2026
- Results of operations · Other material eventMar 16, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KJun 1, 2026
- 8-KMay 27, 2026
- 8-KMay 22, 2026
- SCHEDULE 13G/AMay 12, 2026
- 10-QMay 11, 2026
- 8-KMay 11, 2026
- 8-KMay 4, 2026
- SCHEDULE 13G/AApr 27, 2026
- 8-KApr 20, 2026
- DEFA14AApr 16, 2026
- DEF 14AApr 16, 2026
- 8-KApr 1, 2026
- 10-KMar 16, 2026
- 8-KMar 16, 2026
- SCHEDULE 13GMar 10, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.